Revolutionising Early-Stage Breast Cancer Treatment: How the MAF Test® Enhances Precision Care with Biomarker-Driven Insights
The MAF Test® by Inbiomotion is an advanced diagnostic tool designed to enhance treatment decisions in early-stage breast cancer. By detecting MAF gene amplification, the test provides oncologists with critical insights into a patient’s risk of developing bone metastasis. This information is vital for identifying patients who may benefit from bisphosphonate therapy, such as zoledronic acid, allowing for more personalized and effective treatment plans.
